Cardiff Oncology Inc
CRDF2.530USD
-0.110-4.17%
Horário de mercado （ET）Cotações atrasadas em 15 min
168.31MValor de mercado
PerdaP/L TTM
Mais detalhes de Cardiff Oncology Inc Empresa
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Informações da empresa
Código da empresaCRDF
Nome da EmpresaCardiff Oncology Inc
Data de listagemJul 27, 2004
CEODr. Mark Erlander, Ph.D.
Número de funcionários32
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 27
Endereço11055 Flintkote Ave
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121
Telefone18589527570
Sitehttps://cardiffoncology.com/
Código da empresaCRDF
Data de listagemJul 27, 2004
CEODr. Mark Erlander, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
20.00K
--
Dr. Tod Smeal, Ph.D.
Dr. Tod Smeal, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger Sidhu, M.D.
Dr. Roger Sidhu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gary William Pace, Ph.D.
Dr. Gary William Pace, Ph.D.
Independent Director
Independent Director
1.33M
+26.05%
Ms. Lale White
Ms. Lale White
Independent Director
Independent Director
113.79K
--
Mr. James E. (Jamie) Levine
Mr. James E. (Jamie) Levine
Chief Financial Officer
Chief Financial Officer
67.72K
+12.86%
Dr. Rodney S. Markin, M.D., Ph.D.
Dr. Rodney S. Markin, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
31.06K
--
Dr. James O. Armitage, M.D.
Dr. James O. Armitage, M.D.
Independent Director
Independent Director
27.49K
--
Dr. Mark Erlander, Ph.D.
Dr. Mark Erlander, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
24.48K
--
Detalhamento da receita
FY2025Q1
FY2024
FY2023
FY2022
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
109.00K
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Commodore Capital LP
8.09%
The Vanguard Group, Inc.
5.60%
BlackRock Institutional Trust Company, N.A.
5.32%
William Blair & Company, L.L.C. (Research)
3.79%
Pfizer Inc
3.63%
Other
73.56%
Investidores
Investidores
Proporção
Commodore Capital LP
8.09%
The Vanguard Group, Inc.
5.60%
BlackRock Institutional Trust Company, N.A.
5.32%
William Blair & Company, L.L.C. (Research)
3.79%
Pfizer Inc
3.63%
Other
73.56%
Tipos de investidores
Investidores
Proporção
Investment Advisor
17.41%
Hedge Fund
14.56%
Investment Advisor/Hedge Fund
8.49%
Research Firm
5.32%
Corporation
3.63%
Individual Investor
2.01%
Private Equity
0.86%
Bank and Trust
0.18%
Insurance Company
0.03%
Other
47.51%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
209
34.93M
52.51%
+1.36M
2025Q1
212
33.90M
51.14%
+3.13M
2024Q4
197
29.71M
44.66%
+10.83M
2024Q3
176
18.97M
39.69%
-1.89M
2024Q2
177
19.40M
43.04%
+3.79M
2024Q1
190
14.89M
33.18%
-2.33M
2023Q4
185
11.58M
25.77%
-8.71M
2023Q3
197
11.37M
25.45%
-9.63M
2023Q2
203
11.90M
26.66%
-13.64M
2023Q1
216
12.90M
29.30%
-10.68M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Commodore Capital LP
5.38M
8.09%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.12M
4.68%
+830.45K
+36.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.54M
5.32%
+907.00K
+34.45%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
1.75M
2.63%
+1.47M
+520.96%
Mar 31, 2025
Pfizer Inc
2.41M
3.63%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.45M
2.17%
+152.69K
+11.82%
Mar 31, 2025
Acorn Capital Advisors, LLC
1.44M
2.17%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.39M
2.1%
+411.55K
+41.87%
Mar 31, 2025
Pace (Gary William)
1.06M
1.59%
+7.80K
+0.74%
Apr 28, 2025
State Street Global Advisors (US)
940.28K
1.41%
+91.70K
+10.81%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Vanguard US Momentum Factor ETF
0.05%
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Ver Mais
Vanguard US Momentum Factor ETF
Proporção0.05%
iShares Micro-Cap ETF
Proporção0.04%
Global X Russell 2000 ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
